NRT6003 is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Chengdu New Radiomedicine Technology Co. LTD (1). The most-studied condition is Unresectable Hepatocellular Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
NCT07657273 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 2 | Not yet open | Second Affiliated Hospital of Guangzhou Medical University | China |
|
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma
|
Phase 3 | Active, closed | Chengdu New Radiomedicine Technology Co. LTD. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Chengdu New Radiomedicine Technology Co. LTD. | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name NRT6003 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Chengdu New Radiomedicine Technology Co. LTD (1) and Second Affiliated Hospital of Guangzhou Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NRT6003 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NRT6003 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NRT6003 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.